Our portfolio
CEPI is working to end pandemics by supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches.
Explore our portfolio
CEPI funds the development of vaccine candidates against our priority pathogens and vaccine platforms to enable rapid development of vaccines against Disease X. Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in. Filter information by developer, disease, phase of development, or vaccine type. You can also download a summary of our active portfolio.
Portfolio: list view
Affinivax
Affinivax - Broadly Protective Coronavirus Vaccine
CEPI supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.
The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.
CEPI funding has been discontinued.
Akagera Medicines
Akagera - Disease X
CEPI is providing up to US $1.5 million to Akagera Medicines to demonstrate the pre-clinical proof of concept of their lipid nanoparticles (LNPs) and modified mRNA for the development of a multivalent influenza vaccine.
Their LNP formulation could optimise delivery of mRNA and reduce potential LNP-associated adverse events.
The technology could also improve the stability of the mRNA-based vaccines, removing the need for frozen storage to bolster equitable vaccine access.
Benefits could also include enhanced shelf life, reduced Cost of Goods, and a reduction in the required effective dose which would extend the number of doses that could be produced.
Amplitude Therapeutics
Amplitude Therapeutics - Disease X
Researchers at Amplitude Therapeutics will perform preclinical studies that assess whether their trans-amplifying mRNA vaccine approach could provide a simplified alternative to the self-amplifying mRNA vaccine technique being used today.
Trans-amplifying mRNA vaccines consist of two separate, short RNA fragments - one encoding the antigen and one encoding the replicase.
By separating out the target antigen and replicase sequences, the vaccine could be more easily produced in vaccine manufacturing facilities. Compared to conventional mRNA vaccines, the design could also mean up to 100 times less antigen-encoded RNA is needed per dose and the replicase enzyme can be produced ahead of an outbreak as it does not need to be combined with the target antigen sequence.
Auro vaccines & PATH
Auro Vaccines - Nipah
CEPI is providing up to US $25 million to advance development of the Nipah virus vaccine candidate, HeV-Sg-V.
HeV-sG-V Nipah is a recombinant subunit vaccine that contains a portion of the G glycoprotein of Hendra virus, a henipavirus closely related to Nipah.
HeV-sG-V became the first-ever Nipah vaccine candidate to enter in-human testing in 2020. The trial, sponsored by Auro Vaccines, investigated the safety, tolerability, and immunogenicity of the vaccine candidate.
PATH is leading clinical operations and CEPI is funding the programme through Phase 2 clinical trials. Under the terms of the original agreement awarded by CEPI, Emergent BioSolutions has provided contract development and manufacturing services to produce the Phase 1 clinical trial material. Through a separate agreement with Auro Vaccines, Emergent has an exclusive option to license and assume control of development activities for the Nipah virus vaccine candidate.
Bharat Biotech, University of Sydney, and ExcellGene
Bharat Biotech, University of Sydney, ExcellGene SA - Broadly Protective Coronavirus Vaccine
CEPI is providing up to US$19.3 million to establish preclinical and clinical proof of concept for an adjuvanted subunit ‘variant-proof’ SARS-CoV-2 vaccine candidate being developed by an international consortium comprising Bharat Biotech International Ltd, University of Sydney and ExcellGene SA.
CEPI is funding the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.
The vaccine approach and scalable manufacturing process trialled as part of this project could also enable rapid development of broadly protective vaccines against other Betacoronaviruses, as well as vaccines against Disease X.